Insmed (INSM) reported a first quarter net loss of $163.6 million, or $0.76 per share, compared to a net loss of $256.6 million, or $1.42 per share, a year ago. Product revenues, net, was $305.96 million compared to $92.82 million.
The company reiterated 2026 BRINSUPRI revenue guidance of at Least $1 billion and 2026 ARIKAYCE revenue guidance of $450 million to $470 million.
As of March 31, 2026, Insmed had cash, cash equivalents, and marketable securities totaling approximately $1.2 billion.
In pre-market trading on NasdaqGS, Insmed shares are down 5.15 percent to $130.04.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.